Essential Role of Pepsin in Pathogenesis of Acid Reflux Esophagitis in Rats
- 133 Downloads
Pepsin, a protease activated by gastric acid, is a component of the refluxate, yet the role of pepsin in the pathogenesis of reflux esophagitis has not been well studied. In the present study, we examined the effect of pepstatin, a specific inhibitor of pepsin, on acid reflux esophagitis. Acid reflux esophagitis was induced in rats by ligating both the pylorus and the forestomach for 3 or 4 hr. Pepstatin, ecabet Na (the anti-ulcer drug), and L-glutamine were administered intragastrically after the ligation. Pepstatin or ecabet Na, given intragastrically, significantly prevented esophageal lesions, even though they did not affect basal acid secretion in pylorus-ligated rats. Pepstatin significantly inhibited pepsin activity in vivo and in vitro, while ecabet Na inhibited this activity in vitro. By contrast, L-glutamine given intragastrically aggravated the lesions in a dose-dependent manner, but even in the presence of L-glutamine the development of esophageal lesions was totally prevented by coadministration of pepstatin or ecabet Na. L-Glutamine increased the pH of gastric contents to approximately 2.0, the optimal pH for the proteolytic activity of pepsin in vitro. In addition, intragastric administration of exogenous pepsin worsened the severity of esophageal damage. These results suggest that pepstatin is highly effective against acid reflux esophagitis, without influencing acid secretion, while L-glutamine aggravated these lesions by increasing the pepsin activity by shifting the intraluminal pH to the optimal pH range for proteolytic action. It is assumed that pepsin plays a major pathogenic role in the development of acid reflux esophagitis.
Key Wordsacid reflux esophagitis pepsin pathogenesis L-glutamine rat model
Unable to display preview. Download preview PDF.
- 3.Meuwissen SGM, Klinkenberg-Knol EC: Treatment of reflux oesophagitis with H2-receptor antagonist. Scand J Gastroenterol 23 (Suppl 146):201–213, 1988Google Scholar
- 4.Klinkenberg-Knol EC, Jansen JBMJ, Lamers CBHQ, Neils F, Snel P, Meuwissen SGM: Use of omeprazole in the management of reflux oesophagitis resistant to H2-receptor antagonists. Scand J Gastroenterol 24 (Suppl 166):88–93, 1989Google Scholar
- 6.Hirschowitz BI: Pepsin and esophagitis. Yale J Biol Med 72:133–143, 1991Google Scholar
- 9.Umezawa H, Aoyagi T, Morishima H, Matsuzaki M, Hamada M, Takeuchi T: Pepstatin, a new pepsin inhibitor produced by actinomycetes. J Antibioti 23:259–262, 1970Google Scholar
- 10.Kunimoto S, Aoyagi T, Morishima H, Takeuchi T, Umezawa H: Mechanism of inhibition of pepsin by pepstatin J. Antibiot 25:251–255, 1972Google Scholar
- 15.Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, Lloyd D, Havu N, Frame MH, Roman J, Walan A, Group LT: Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 118:661–669, 2000PubMedGoogle Scholar
- 17.Kinoshita M, Endo M, Yasoshima A, Saito N, Yamasaki K, Chishima S, Narita H. Ecabet sodium, a novel locally-acting anti-ulcer agent, protects the integrity of the gastric mucosal gel layer from pepsin-induced disruption in the rat. Aliment Pharmacol Ther 13:687–694, 1999Google Scholar